Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$734M |
| 2 |
Boeing
BA
|
+$493M |
| 3 |
Pfizer
PFE
|
+$478M |
| 4 |
UnitedHealth
UNH
|
+$440M |
| 5 |
Honeywell
HON
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.05B |
| 2 |
Advanced Micro Devices
AMD
|
+$447M |
| 3 |
TSMC
TSM
|
+$441M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 5 |
ExxonMobil
XOM
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.34% |
| 2 | Technology | 16.84% |
| 3 | Consumer Discretionary | 12.66% |
| 4 | Industrials | 10.11% |
| 5 | Consumer Staples | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Schwab International Equity ETF
SCHF
$69.3B
| $202K | ﹤0.01% |
+11,600
| New | +$199K |
|
3277
State Street SPDR Portfolio Emerging Markets ETF
SPEM
$17.7B
| $201K | ﹤0.01% |
5,900
-73,200
| -93% | -$2.52M |
|
3278
TH International
THCH
$54.5M
| $201K | ﹤0.01% |
+9,880
| New | +$199K |
|
3279
Key Tronic
KTCC
$42.8M
| $200K | ﹤0.01% |
27,500
+3,100
| +13% | +$18.8K |
|
3280
Sana Biotechnology
SANA
$1.1B
| $200K | ﹤0.01% |
61,100
-104,600
| -63% | -$418K |
|
|
ONCT
3281
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $200K | ﹤0.01% |
12,755
+665
| +6% | +$13.1K |
|
|
ADAP
3282
DELISTED
Adaptimmune Therapeutics
ADAP
| $199K | ﹤0.01% |
182,700
-378,273
| -67% | -$586K |
|
3283
Atomera
ATOM
$212M
| $199K | ﹤0.01% |
+31,204
| New | +$211K |
|
|
AUTL
3284
Autolus Therapeutics
AUTL
$564M
| $199K | ﹤0.01% |
108,400
+62,100
| +134% | +$121K |
|
3285
Enlivex Ltd
ENLV
$31M
| $199K | ﹤0.01% |
3,646
+33
| +0.9% | +$1.99K |
|
3286
Jasper Therapeutics
JSPR
$28.7M
| $199K | ﹤0.01% |
11,020
+4,480
| +69% | +$82.8K |
|
3287
Quantum-Si Incorporated
QSI
$172M
| $199K | ﹤0.01% |
112,856
+75,300
| +201% | +$149K |
|
3288
Taysha Gene Therapies
TSHA
$1.92B
| $199K | ﹤0.01% |
249,600
-270,200
| -52% | -$349K |
|
|
VIRX
3289
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $199K | ﹤0.01% |
125,299
-14,488
| -10% | -$26.3K |
|
3290
Aemetis
AMTX
$126M
| $196K | ﹤0.01% |
84,660
-118,155
| -58% | -$440K |
|
3291
US Global Investors
GROW
$38.7M
| $196K | ﹤0.01% |
73,368
+32,045
| +78% | +$92.4K |
|
3292
Savara
SVRA
$1.08B
| $196K | ﹤0.01% |
100,700
+30,600
| +44% | +$68.9K |
|
|
CMLS
3293
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $196K | ﹤0.01% |
53,046
+16,146
| +44% | +$90.7K |
|
3294
Korro Bio
KRRO
$197M
| $194K | ﹤0.01% |
7,730
+751
| +11% | +$85.6K |
|
3295
Comstock
LODE
$265M
| $194K | ﹤0.01% |
57,588
+25,567
| +80% | +$101K |
|
|
TIGR
3296
UP Fintech Holding
TIGR
$833M
| $194K | ﹤0.01% |
58,300
-6,000
| -9% | -$22.1K |
|
3297
ProShares UltraShort FTSE Europe
EPV
$10.2M
| $190K | ﹤0.01% |
+3,680
| New | +$202K |
|
3298
VirTra
VTSI
$37.3M
| $190K | ﹤0.01% |
47,600
-1,300
| -3% | -$5.85K |
|
|
FTH
3299
Faeth Therapeutics
FTH
$759M
| $188K | ﹤0.01% |
6,260
-2,368
| -27% | -$70.2K |
|
3300
Gain Therapeutics
GANX
$92.6M
| $187K | ﹤0.01% |
38,700
+5,500
| +17% | +$22.5K |
|
Similar funds
Jim Simons's Q1 2023 Portfolio in Review
As of Q1 2023, Jim Simons held 4,600 positions worth $75.4B, up 3.1% from $73.1B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q1 2023 filing shows 524 new, 1,665 increased, 1,689 reduced and 668 closed positions. Its largest new stake was Honeywell: 1,937,917 shares worth $349M. The largest sale was Apple, an estimated $1.05B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q1 2023 buy was Honeywell: 1,937,917 shares worth $349M.
- Jim Simons added most to First Republic Bank in Q1 2023, an estimated $734M increase.
- Jim Simons's biggest Q1 2023 reduction was Apple, cutting an estimated $1.05B.
- Jim Simons fully exited Advanced Micro Devices in Q1 2023, selling an estimated $447M.
- Jim Simons's ten largest holdings make up 11% of its $75.4B portfolio in Q1 2023.
- Jim Simons opened 524 new positions and closed 668 in Q1 2023.
- Jim Simons's portfolio value rose 3.1% quarter-over-quarter to $75.4B.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.